

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – UPDATE ON AN INHALATION GAS PRODUCT

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 20 February 2020, the New Drug Application (“**NDA**”) of INOmax[®] (nitric oxide) gas for inhalation (“**INOmax[®]**”) by Lee’s Pharmaceutical (HK) Limited, a wholly-owned subsidiary of the Company, has been granted priority review for pediatric orphan disease by China National Medical Products Administration (“**NMPA**”). INOmax[®] is an inhaled nitric oxide pharmaceutical for treating term and near-term neonates (>34 weeks) with hypoxic respiratory failure (“**HRF**”) associated with pulmonary hypertension.

According to data from China National Bureau of Statistics, the number of newborns in 2019 was about 14.65 million. As reported by Liu et al. in *Respiratory Research* (2019) 20:174, the incidence of China ranges from 2 to 6 per 1,000 live births and the mortality rate is about 10–20%.

As a result, it is expected that the effort to make INOmax[®] available in China will provide better therapeutics and improve lives of underserved patients therein.

INOmax[®] is an in-licensed product from Mallinckrodt Pharmaceuticals (“**Mallinckrodt**”) for the People’s Republic of China, Hong Kong, Macau and Taiwan. Mallinckrodt is a global biopharmaceutical company.

* For identification purposes only

ABOUT INOmax®

INOmax® is a therapy approved by U.S. Food and Drug Administration (“FDA”) for the treatment of HRF associated with pulmonary hypertension (“PPHN”) in term and near-term infants greater than 34 weeks gestational age. PPHN is a serious condition in which blood vessels in the lungs constrict, making it difficult to oxygenate blood, often resulting in HRF. INOmax® is a vasodilator which selectively relaxes pulmonary blood vessels and, in conjunction with ventilatory support and other appropriate agents, improves oxygenation in this fragile newborn population.

ABOUT LEE’S PHARMACEUTICAL HOLDINGS LIMITED

The Company is a public biopharmaceutical company with over 25 years of operations in China’s pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets 17 products in the PRC. The Company focuses on several different areas such as cardiovascular, rare diseases, ophthalmology, oncology, gynecology and dermatology. It has more than 60 products under different development stages stemming from both internal R&D and acquisition of licensing and distribution rights from various U.S., European and Japanese companies.

The Company has committed to the development of pharmaceutical products for rare diseases in China since 2012, and is a founding member of Shanghai Foundation for Rare Disease and a member of China Alliance of Rare Disease. Besides INOmax®, the Group is also developing other orphan drugs, including but not limited to Sodium Phenylbutyrate, Treprostinil, Surfaxin, Tekglutik®, Neridronate and Anfibatide. In 2016, Anfibatide received orphan drug designation from U.S. FDA for treatment of thrombotic thrombocytopenic purpura (TTP).

Additional information is available at <https://www.leespharm.com/>.

By order of the Board
Lee’s Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 16 March 2020

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.